Revesz syndrome (RS) is a rare genetic disease. It is generally regarded in literature as a less commonly occurring, more severe, variant of dyskeratosis congenita (DC). Thus the former exhibit features that are typical of DC, such as abnormal nail formation, skin hyperpigmentation, and oral leukoplakia [1]. RS occurs as a result of genetic mutation, specifically in the TINF2 gene coding for a protein that is involved in telomere synthesis. The same gene has been found to be responsible for some forms of DC.

The phenotypic features of RS have not been fully delineated, as there is a small number of reported cases, amongst which there is great variation in clinical presentation [2] [3].

Features that are typical of RS include ocular and periorbital abnormalities such as lid deformities, exudative retinopathy, vitreous hemorrhage, corneal or vitreous opacification, and conjunctival scarring. These features manifest in childhood and may cause a decrease in visual acuity, or blindness. Within the central nervous system (CNS), patients with RS often show a hypoplastic cerebellum and cerebral calcifications. Some patients may present with ataxia [4].

Affected individuals have a high risk of developing malignant tumors and bone marrow failure. The latter may result in neutropenia, pancytopenia, and aplastic anemia, frequently appearing early in life. Additional features of RS include sparse hair, psychomotor retardation, and intrauterine growth restriction [5] [6].

The diagnosis of Revesz syndrome is reached via a combination of patient history, clinical findings, laboratory results, and genetic testing. It is important that the correct diagnosis of RS be made early, as the risk of developing malignancies, in those affected by the condition, is significant. Moreover, the aforementioned individuals may require and benefit from urgent treatment.

Molecular and genetic studies should be carried out to establish the presence of gene mutations indicative of RS, as well as abnormal telomere lengths [7]. Possible laboratory methods include PCR (polymerase chain reaction), Southern blot, flow cytometry, and fluorescence in situ hybridization (FISH) with immunostaining, [8] [9].

It has been observed that up to half of patients with DC have no observable genetic mutations. The possibility of the syndrome in such patients cannot be ruled out, however, as a diagnosis can be made based on the presence of clinical features consistent with the disease, in addition to molecular studies revealing short telomeres [10].

In older individuals, DC may present with increasingly diverse symptoms that may deviate from the common presentation [11]. The criteria for testing patients for DC or RS may depend on the protocol of a given health facility.

There is no cure for Revesz Syndrome, and treatment focuses on managing symptoms and complications:

• Hematopoietic Stem Cell Transplantation (HSCT): This may be considered for severe bone marrow failure.
• Supportive Care: Includes blood transfusions, antibiotics for infections, and medications to stimulate blood cell production.
• Regular Monitoring: For potential complications like cancer or pulmonary issues.
• Multidisciplinary Approach: Involving specialists in hematology, dermatology, neurology, and ophthalmology.

The prognosis for Revesz Syndrome varies depending on the severity of symptoms and the success of treatments like HSCT. Patients with severe bone marrow failure or significant organ involvement may have a reduced life expectancy. Early diagnosis and comprehensive management can improve quality of life and outcomes.

Revesz Syndrome is caused by mutations in the TINF2 gene, which plays a role in maintaining telomeres. Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. Mutations in TINF2 lead to accelerated telomere shortening, contributing to the symptoms of the syndrome.

Revesz Syndrome is extremely rare, with only a few cases reported in the medical literature. It affects both males and females and can occur in any ethnic group. Due to its rarity, the exact prevalence is unknown.

The pathophysiology of Revesz Syndrome involves defective telomere maintenance due to TINF2 gene mutations. Shortened telomeres lead to premature cell aging and death, particularly affecting rapidly dividing cells in the bone marrow, skin, and other tissues. This results in the characteristic symptoms of the syndrome.

As a genetic disorder, there is no known way to prevent Revesz Syndrome. Genetic counseling may be beneficial for families with a history of the condition to understand the risks and implications for future pregnancies.

Revesz Syndrome is a rare genetic disorder characterized by bone marrow failure, skin abnormalities, and neurological issues. It is caused by mutations in the TINF2 gene, leading to defective telomere maintenance. Diagnosis involves clinical evaluation and genetic testing, while treatment focuses on managing symptoms. The prognosis varies, and there is no known prevention.

For patients and families affected by Revesz Syndrome, understanding the condition is crucial. It is a rare genetic disorder that affects multiple body systems, primarily the bone marrow. Symptoms can vary widely, and management requires a team of specialists. While there is no cure, treatments are available to help manage symptoms and improve quality of life. Genetic counseling can provide valuable information for affected families.

1. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet. 2008;82(2):501–509.
2. Revesz T, Fletcher S, al-Gazali LI, DeBuse P. Bilateral retinopathy, aplastic anaemia, and central nervous system abnormalities: a new syndrome? J Med Genet. 1992;29(9):673-675.
3. Kajtár P, Méhes K. Bilateral coats retinopathy associated with aplastic anaemia and mild dyskeratotic signs. Am J Med Genet. 1994;49(4):374-377.
4. Sasa GS, Ribes-Zamora A, Nelson ND, Bertuch AA. Three novel truncating TINF2 mutations causing severe dyskeratosis congenita in early childhood. Clin Genet. 2012;81(5):470-478.
5. Riyaz A, Riyaz N, Jayakrishnan MP, Mohamed Shiras PT, Ajith Kumar VT, Ajith BS. Revesz syndrome. Indian J Pediatr. 2007;74(9):862-863.
6. Scheinfeld MH, Lui YW, Kolb EA, et al. The neuroradiological findings in a case of Revesz syndrome. Pediatr Radiol. 2007;37(11):1166-1170.
7. Savage SA, Alter BP. The role of telomere biology in bone marrow failure and other disorders. Mech Ageing Dev. 2008;129(12):35–47.
8. Baird DM. New developments in telomere length analysis. Exp Gerontol.May;40(5):363-368.
9. Lin KW, Yan J. The telomere length dynamic and methods of its assessment. J Cell Mol Med. 2005;9(4):977–989.
10. Rosenberg P, Giri N, Savage SA, Alter BP. Cancer Epidemiology in the National Cancer Institute Inherited Bone Marrow Failure Syndromes Cohort: First Report. Blood. 2008;112(11):40.
11. Dokal I, Vulliamy T, Mason P, Bessler M. Clinical utility gene card for: dyskeratosis congenita. Eur J Hum Genet. 2011;19(11).